We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKronos Bio Inc

Kronos Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-07-21T14:25:57.395193Z
Market Cap
45.36M

Momentum Score

…

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.69
Low
2.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
7.59M
Revenue Per Share
0.13
Gross Profit TTM
0.00M
Debt / Equity
0.18
ROE
-64.20%
Net Debt
-36.05M
ROCE
-73.91%
Diluted EPS TTM
-1.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -133.20M -151.08M -88.44M -16.12M -6.72M
Net income -129.29M -149.10M -64.09M -15.42M -6.72M
Selling general administrative 43.40M 38.49M 14.79M 3.37M 1.61M
Reconciled depreciation 2.27M 1.98M 0.84M 0.36M 0.09M
Ebit -139.38M -151.40M -58.04M -16.82M -6.64M
Ebitda -137.12M -151.08M -84.55M -16.46M -6.55M
Depreciation and amortization 2.27M 0.32M -26.51M 0.36M 0.09M
Non operating income net other 3.91M 0.32M -26.51M - -
Operating income -137.12M -151.40M -58.04M -16.82M -6.64M
Other operating expenses 137.12M 151.40M 58.04M 16.82M 6.64M
Interest expense -2.27M 1.66M 3.89M 0.00M 0.08M
Interest income 3.91M 0.32M 0.90M - 0.00M
Net interest income 3.91M 0.32M -2.99M 0.70M -0.08M
Income tax expense -3.91M -1.98M -24.36M -0.70M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 137.12M 151.40M 58.04M 16.82M 6.64M
Total other income expense net 3.91M 0.32M -30.40M 0.70M -0.08M
Net income from continuing ops -133.20M -151.08M -88.44M -16.12M -6.72M
Net income applicable to common shares -133.20M -151.08M -88.44M -16.12M -6.72M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 213.28M 294.94M 391.48M 511.96M 102.69M
Other current assets 5.78M 6.11M 8.04M 6.74M 0.92M
Total liab 54.20M 50.44M 46.38M 46.45M 125.89M
Total stockholder equity 159.08M 244.50M 345.10M 465.52M -23.20M
Other current liab 11.34M 14.09M 1.46M 2.39M 0.06M
Common stock 0.06M 0.06M 0.06M 0.05M 0.01M
Capital stock 0.06M 0.06M 0.06M 0.05M 0.01M
Retained earnings -508.86M -396.19M -262.98M -111.91M -23.46M
Other liab - 0.21M 1.10M 2.47M 0.07M
Other assets - 3.19M 2.14M 78.52M 0.43M
Cash 64.33M 75.97M 339.51M 462.06M 32.57M
Total current liabilities 24.70M 21.49M 13.63M 12.86M 2.70M
Current deferred revenue 9.58M - 9.06M 4.97M 0.82M
Net debt -36.05M -44.88M -305.75M -430.00M -32.04M
Short term debt 2.89M 2.35M 2.11M 0.94M 0.32M
Short long term debt total 28.27M 31.09M 33.76M 32.06M 0.53M
Other stockholder equity 667.86M 641.42M 608.06M 65.43M 0.27M
Property plant equipment - 12.98M 41.78M 40.97M 4.19M
Total current assets 178.78M 244.29M 347.55M 419.80M 93.30M
Long term investments 1.99M 9.76M 0.00M 49.00M 4.76M
Net tangible assets - 244.50M 345.10M 465.52M -23.20M
Short term investments 108.67M 162.21M 141.24M 165.05M 59.61M
Net receivables - 0.57M 0.82M 0.61M 0.20M
Inventory - -10.33M -0.82M -49.61M -
Accounts payable 0.88M 5.05M 1.00M 4.55M 1.51M
Accumulated other comprehensive income 0.02M -0.79M -0.04M -0.02M -0.02M
Common stock total equity - 0.06M 0.06M 0.05M 0.01M
Retained earnings total equity - -396.19M -262.98M -111.91M -
Non currrent assets other 0.58M 3.19M 2.14M 2.19M 0.43M
Non current assets total 34.50M 50.65M 43.92M 92.16M 9.38M
Capital lease obligations 28.27M 31.09M 33.76M 32.06M 0.53M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -31.64M 67.98M -160.24M -67.58M -1.07M
Change to liabilities 8.30M -0.72M 2.81M 0.72M -0.03M
Total cashflows from investing activities -32.22M 63.72M -160.24M -67.58M -1.07M
Net borrowings - -0.01M 151.24M -0.03M -0.07M
Total cash from financing activities 0.85M 4.46M 415.61M 105.01M 16.22M
Change to operating activities 2.15M 1.57M 3.65M -0.44M 0.12M
Net income -133.20M -151.08M -88.44M -16.12M -6.72M
Change in cash -122.30M -49.74M 217.47M 22.34M 8.70M
Begin period cash flow 200.30M 250.04M 32.57M 10.23M 1.52M
End period cash flow 78.00M 200.30M 250.04M 32.57M 10.23M
Total cash from operating activities -90.93M -117.92M -37.91M -15.08M -6.44M
Issuance of capital stock - 0.00M 263.73M 105.04M 16.29M
Depreciation 2.27M 1.98M 0.84M 0.36M 0.09M
Sale purchase of stock 0.38M 1.34M 264.37M - -
Other cashflows from financing activities -32.22M 3.13M 151.92M 104.92M 16.29M
Change to netincome 32.17M 26.70M 39.34M 0.40M 0.10M
Capital expenditures 0.58M 4.26M 9.57M 2.95M 1.07M
Cash flows other operating 0.08M 1.20M -0.25M - -
Cash and cash equivalents changes -122.30M -49.74M 217.47M - -
Change in working capital 6.18M -1.62M 6.46M 0.28M 0.09M
Stock based compensation 31.14M 26.21M 3.75M 0.11M 0.03M
Other non cash items 2.69M 2.59M 39.15M 0.29M 0.07M
Free cash flow -91.50M -122.18M -47.48M -18.03M -7.52M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Kronos Bio Inc

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

1300 South El Camino Real, San Mateo, CA, United States, 94402

650 781 5200

https://www.kronosbio.com

61

Name Title Year Born
Dr. Norbert W. Bischofberger Ph.D. Pres, CEO & Director 1956
Mr. Joshua A. Kazam Co-Founder & Director 1977
Dr. Yasir B. Al-Wakeel BCh, BM, MA CFO & Head of Corp. Devel. 1982
Ms. Barbara A. Kosacz J.D. COO, Sec. & Gen. Counsel 1958
Dr. Christopher Dinsmore Ph.D. Chief Scientific Officer 1967
Dr. Jorge F. DiMartino M.D., Ph.D. Chief Medical Officer & Exec. VP of Clinical Devel. 1964
Stephanie Yao Exec. Director of Investor Relations & Corp. Communications NA
Ms. Marni Kottle Sr. VP of Corp. Communications & Investor Relations NA
Mr. Charles Lin Ph.D. Sr. VP of Biology NA
Dr. Elizabeth A. Olek D.O., M.P.H. Sr. VP of Clinical Devel. 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…